Agenus Inc. announced a private placement to raise $85 million upfront, with the potential for an additional $255 million from warrant exercises, totaling up to $340 million. This financing is specifically earmarked to fund the registrational Phase 3 trial (ROBBIN) for their BOT+BAL combination in neoadjuvant MSS colon cancer, a market with significant unmet needs and substantial sales opportunity, extending their runway through 2031.
Agenus Inc. has secured a significant financing package, starting with $85 million upfront and potentially reaching $340 million through warrant exercises. This capital infusion is critical as it directly funds the planned registrational Phase 3 ROBBIN trial for their BOT+BAL combination in MSS colon cancer, a disease with a large addressable market ($7 billion annually in the US) and no new curative-intent therapies in over two decades. The financing, which includes a premium pricing for shares and warrants, extends Agenus's cash runway through year-end 2031, significantly de-risking their clinical development path for this promising asset. This is a strong positive for Agenus, providing the necessary resources to advance a potentially transformative therapy and offering long-term stability for the company's operations.